Clinical Trials in Boston

Showing 4301-4320 of 17,836 trials

The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related Diabetes

NCT05723445

This study will evalute the effect of a low glycemic load (LGL diet on dysglycemia, insulin requirements, DXA-derived body composition, gastrointestinal symptoms and quality of life measures in adults with cystic fibrosis-related diabetes (CFRD). We will use continuous glucose monitors (CGM) to assess the LGL diet both in a controlled setting (via a meal delivery company) and in free-living conditions.

Cystic FibrosisCystic Fibrosis-related DiabetesCystic Fibrosis With Intestinal Manifestations

Rhode Island Hospital15 participantsStarted Sep 2023

Boston, Massachusetts, United States • Providence, Rhode Island, United States

No Longer Available< 1 mile

IC14 for ALS Patients Expanded Access

NCT04309604

The primary objective is to provide the investigational product, IC14, at the dose of 8 mg/kg intravenously every 2 weeks for 12 weeks to 6 participants with amyotrophic lateral sclerosis (ALS). No clinical hypotheses are being tested. An extension for 6 additional doses every 2 weeks will be allowed if the drug is safe and well tolerated.A second extension for 14 doses every 2 weeks will be allowed if the drug is safe and well tolerated.

Amyotrophic Lateral Sclerosis

Implicit Bioscience

Boston, Massachusetts, United States

COMPLETEDPhase 1/2< 1 mile

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

NCT05259696

This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.

OncologyMelanomaOvarian Cancer+14 more

Palleon Pharmaceuticals, Inc.69 participantsStarted Feb 2022

La Jolla, California, United States • Los Angeles, California, United States • Stanford, California, United States +10 more locations

The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related Diabetes

IC14 for ALS Patients Expanded Access

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

Find Trials by Condition in Boston

TransHealthGUIDE: Transforming Health for Gender-Diverse Young Adults

PRIMARY Ancillary Substudy

Reconnecting to Ourselves and Others in Virtual Meetings (ROOM)

Families Left Behind

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial

A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

STICH3C Cardiac Magnetic Resonance Observational Study

A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

The ReTAVI Prospective Observational Registry

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant

Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

PTG-300 in Subjects With Hereditary Hemochromatosis

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)